Mumbai, May 21: IOL Chemicals and Pharmaceuticals Ltd., one of the leading Active Pharmaceutical Ingredient (API) manufacturers, announced its Financial Results for the quarter and full year ended 31st March 2026.
Commenting on the performance, Mr Vikas Gupta, Joint Managing Director said, “Ǫ4FY2c marked a strong performance for IOL, with the Company delivering its highest-ever quarterly revenue, driven by healthy momentum across both Pharmaceuticals and Chemicals businesses. The quarter also witnessed significant improvement in profitability, with EBITDA and PAT recording strong growth, while margins expanded meaningfully on a YoY basis, supported by a better product mix and sustained focus on operational efficiencies.
The Pharmaceuticals business continued to demonstrate strong growth, led by increasing contribution from the non-Ibuprofen portfolio. Key products such as Paracetamol, Metformin, and other APIs witnessed healthy traction, reflecting the Company’s ongoing diversification strategy. The improving product mix, combined with IOL’s position as one of the lowest-cost producers in key molecules, supported stronger profitability and margin expansion in the Pharma segment. The company also continues to undertake capacity additions across select non- ibuprofen APIs as a part of its strategy to strengthen presence in value-added APIs.
The Chemicals business also delivered strong performance during the quarter, with segment EBIT nearly doubling YoY, supported by improved realizations, stable demand conditions, and operational efficiencies. Capacity enhancements in Ethyl Acetate, Acetic Anhydride along with addition of Triacetin Capacity will further strengthen the Company’s manufacturing capabilities, support backward integration and drive future growth.
During the year, the Company incurred capex of around Rs. 164 crore towards capacity expansion, product & infrastructure development, process automation, and operational improvements, funded through internal accruals. Looking ahead, IOL remains focused on driving disciplined expansion, deepening its presence in regulated as well as non-regulated markets, and enhancing operational efficiencies, supported by a diversified product portfolio and a strong execution track record.”